Survodutide side effects (Phase 2 data) Nausea: 56% of participants Vomiting: 27% Diarrhea: 22% Constipation: 21% Discontinuation due to adverse events: 24.6% Serious adverse events: 4.2% In the MASH trial, rates were even higher: nausea 66%, diarrhea 49%, vomiting 41%
However, their effectiveness depends on dosage, bioavailability, and individual health status, necessitating careful, evidence based application
10.3390/molecules200916970 7 DattaS
(1997) Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols
The Food and Drug Administration of Philippines have issued a position paper with a public warning regarding the safety of off-label use of glutathione injection [Box 5] and the adverse drug reactions reported from the use of intravenous glutathione for skin lightening [Box 6]